Molecule Details
InChIKeyWLAVZAAODLTUSW-UHFFFAOYSA-N
Compound NameSitravatinib
Canonical SMILESCOCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)cc4F)c3s2)nc1
Clinical Status Data-mined Candidate
Targets (Human+Pathogen)7
Pfam Stratification Homologous
Avg pChEMBL8.21
SourceChEMBL;BindingDB
2D Structure
2D structure
Activity Profile
DrugBank Annotations
DrugBank ID DB15036
Drug NameSitravatinib
CAS Number1123837-84-2
Groups investigational
ATC Codes L01EX26
DescriptionSitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma).

Categories: Amides Amines Aniline Compounds Antineoplastic Agents Antineoplastic and Immunomodulating Agents Protein Kinase Inhibitors
Cross-references: CHEMBL3989926 ChemSpider: 52083477 Wikipedia: Sitravatinib ZINC: ZINC000164334830
Target Activities (7)
Target Gene Organism Category Pfam pChEMBL Type Source
P30530 AXL Homo sapiens Human PF00041 PF13927 PF07714 8.8 IC50 ChEMBL;BindingDB
P04629 NTRK1 Homo sapiens Human PF13855 PF16920 PF07714 PF18613 8.3 IC50 ChEMBL;BindingDB
P35968 KDR Homo sapiens Human PF07679 PF00047 PF13895 PF22971 PF07714 PF21339 PF17988 PF22854 8.3 IC50 ChEMBL;BindingDB
P10721 KIT Homo sapiens Human PF00047 PF07714 8.2 IC50 ChEMBL;BindingDB
P36888 FLT3 Homo sapiens Human PF00047 PF07714 8.1 IC50 ChEMBL;BindingDB
Q16620 NTRK2 Homo sapiens Human PF07679 PF13855 PF16920 PF01462 PF07714 8.1 IC50 ChEMBL;BindingDB
P08581 MET Homo sapiens Human PF07714 PF01437 PF01403 PF01833 7.7 IC50 ChEMBL;BindingDB
DrugBank Target Actions (4)
Target Gene Target Name Action Type
P07949 RET Proto-oncogene tyrosine-protein kinase receptor Ret inhibitor targets
P08581 MET Hepatocyte growth factor receptor inhibitor targets
P35916 FLT4 Vascular endothelial growth factor receptor 3 inhibitor targets
P35968 KDR Vascular endothelial growth factor receptor 2 inhibitor targets